002907 华森制药
已收盘 08-28 15:00:00
资讯
新帖
简况
股市必读:华森制药新发布《2026年半年度权益分派实施公告》
证券之星 · 08-28 05:03
股市必读:华森制药新发布《2026年半年度权益分派实施公告》
华森制药(002907)披露收到注射用二乙酰氨乙酸乙二胺再注册批准通知书,8月26日股价上涨2.92%
证券之星 · 08-26 17:27
华森制药(002907)披露收到注射用二乙酰氨乙酸乙二胺再注册批准通知书,8月26日股价上涨2.92%
华森制药最新公告:收到药品再注册批准通知书
证券之星 · 08-25
华森制药最新公告:收到药品再注册批准通知书
华森制药(002907)2026年中报简析:净利润同比增长16.74%,盈利能力上升
证券之星 · 08-22
华森制药(002907)2026年中报简析:净利润同比增长16.74%,盈利能力上升
图解华森制药中报:第二季度单季净利润同比增长122.09%
证券之星 · 08-21
图解华森制药中报:第二季度单季净利润同比增长122.09%
华森制药(002907)披露2026年半年度报告,8月20日股价下跌6.19%
证券之星 · 08-20
华森制药(002907)披露2026年半年度报告,8月20日股价下跌6.19%
8月18日华森制药(002907)龙虎榜数据:机构净买入609.78万元,北向资金净卖出1492.49万元
证券之星 · 08-18
8月18日华森制药(002907)龙虎榜数据:机构净买入609.78万元,北向资金净卖出1492.49万元
华森制药(002907)披露股票交易异常波动公告,8月17日股价上涨10.03%
证券之星 · 08-17
华森制药(002907)披露股票交易异常波动公告,8月17日股价上涨10.03%
华森制药(002907)披露子公司获得创新药《药物临床试验批准通知书》,8月13日股价上涨1.17%
证券之星 · 08-13
华森制药(002907)披露子公司获得创新药《药物临床试验批准通知书》,8月13日股价上涨1.17%
华森制药(002907.SZ):磷酸ORIC-1327滴眼液获得药物临床试验批准
智通财经 · 08-13
华森制药(002907.SZ):磷酸ORIC-1327滴眼液获得药物临床试验批准
股市必读:华森制药新发布《关于公司部分产品拟中选第十二批全国药品集中采购的公告》
证券之星 · 08-05
股市必读:华森制药新发布《关于公司部分产品拟中选第十二批全国药品集中采购的公告》
华森制药(002907)披露部分产品拟中选第十二批全国药品集中采购,8月3日股价上涨1.02%
证券之星 · 08-03
华森制药(002907)披露部分产品拟中选第十二批全国药品集中采购,8月3日股价上涨1.02%
华森制药(002907)披露公司5个产品新入选《国家基本药物目录》,7月9日股价上涨10.04%
证券之星 · 07-09
华森制药(002907)披露公司5个产品新入选《国家基本药物目录》,7月9日股价上涨10.04%
华森制药(002907)披露痛泻宁颗粒获批国家首家中药二级保护品种,6月25日股价下跌1.38%
证券之星 · 06-25
华森制药(002907)披露痛泻宁颗粒获批国家首家中药二级保护品种,6月25日股价下跌1.38%
股市必读:华森制药6月18日涨停收盘,收盘价13.3元
证券之星 · 06-22
股市必读:华森制药6月18日涨停收盘,收盘价13.3元
异动快报:华森制药(002907)6月18日10点22分触及涨停板
证券之星 · 06-18
异动快报:华森制药(002907)6月18日10点22分触及涨停板
华森制药(002907)披露持股5%以上股东股份变动触及1%整数倍及减持时间届满暨减持结果的公告,6月16日股价上涨3.53%
证券之星 · 06-16
华森制药(002907)披露持股5%以上股东股份变动触及1%整数倍及减持时间届满暨减持结果的公告,6月16日股价上涨3.53%
股市必读:6月15日华森制药发布公告,股东减持417.6万股
证券之星 · 06-16
股市必读:6月15日华森制药发布公告,股东减持417.6万股
6月10日华森制药现1笔折价10.62%的大宗交易 合计成交200.97万元
证券之星 · 06-10
6月10日华森制药现1笔折价10.62%的大宗交易 合计成交200.97万元
6月8日华森制药现2笔大宗交易 机构净买入204.98万元
证券之星 · 06-08
6月8日华森制药现2笔大宗交易 机构净买入204.98万元
加载更多
公司概况
公司名称:
重庆华森制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-20
主营业务:
重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是中成药、化学药。
发行价格:
4.53
{"stockData":{"symbol":"002907","market":"SZ","secType":"STK","nameCN":"华森制药","latestPrice":15.52,"timestamp":1787900634000,"preClose":16.32,"halted":0,"volume":29988441,"delay":0,"changeRate":-0.049,"floatShares":339000000,"shares":418000000,"eps":0.1775,"marketStatus":"已收盘","change":-0.8,"latestTime":"08-28 15:00:00","open":15.95,"high":16.12,"low":15.39,"amount":469000000,"amplitude":0.0447,"askPrice":15.52,"askSize":58,"bidPrice":15.51,"bidSize":211,"shortable":0,"etf":0,"ttmEps":0.1775,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.32,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":17.95,"lowLimit":14.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417596314,"isCdr":false,"pbRate":3.92,"roa":"--","peRate":87.43662,"roe":"3.66%","epsLYR":0.1559,"committee":0.778585,"marketValue":6481000000,"turnoverRate":0.0884,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-08-31。","floatMarketCap":5262000000},"requestUrl":"/m/hq/s/002907","defaultTab":"news","newsList":[{"id":"2662035555","title":"股市必读:华森制药新发布《2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662035555","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662035555?lang=zh_cn&edition=full","pubTime":"2026-08-28 05:03","pubTimestamp":1787864596,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘,华森制药报收于16.32元,上涨0.74%,换手率10.3%,成交量34.92万手,成交额5.68亿元。公司公告汇总:华森制药披露2026年半年度权益分派方案,以总股本417,596,314股为基数,每10股派发现金红利0.35元(含税),股权登记日为2026年9月3日,除权除息日为2026年9月4日。交易信息汇总资金流向8月27日主力资金净流出405.82万元,占总成交额0.71%;游资资金净流出3415.9万元,占总成交额6.02%;散户资金净流入3821.72万元,占总成交额6.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662679481","title":"华森制药(002907)披露收到注射用二乙酰氨乙酸乙二胺再注册批准通知书,8月26日股价上涨2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662679481","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662679481?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:27","pubTimestamp":1787736474,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘,华森制药报收于16.2元,较前一交易日上涨2.92%,最新总市值为67.65亿元。该股当日开盘15.88元,最高17.3元,最低15.88元,成交额达7.13亿元,换手率为12.82%。华森制药于近日收到重庆市药品监督管理局核准签发的关于注射用二乙酰氨乙酸乙二胺的《药品再注册批准通知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782046","title":"华森制药最新公告:收到药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662782046?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:41","pubTimestamp":1787647300,"startTime":"0","endTime":"0","summary":"华森制药(002907.SZ)公告称,公司近日收到重庆市药品监督管理局核准签发的关于产品注射用二乙酰氨乙酸乙二胺(0.2g和0.4g)的《药品再注册批准通知书》。该药品适用于预防和治疗各种原因出血。本次获得再注册批准将确保药品正常生产和销售,短期内不会对公司经营业绩产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661550218","title":"华森制药(002907)2026年中报简析:净利润同比增长16.74%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661550218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661550218?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:13","pubTimestamp":1787350439,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期华森制药发布2026年中报。截至本报告期末,公司营业总收入4.14亿元,同比下降6.42%,归母净利润6298.42万元,同比上升16.74%。按单季度数据看,第二季度营业总收入2.02亿元,同比下降0.62%,第二季度归母净利润3019.34万元,同比上升122.09%。本报告期华森制药盈利能力上升,毛利率同比增幅0.88%,净利率同比增幅14.35%。本文数据来源于华森制药2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200005172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661239142","title":"图解华森制药中报:第二季度单季净利润同比增长122.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661239142","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661239142?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:45","pubTimestamp":1787247903,"startTime":"0","endTime":"0","summary":"证券之星消息,华森制药2026年中报显示,上半年度公司主营收入4.14亿元,同比下降6.42%;归母净利润6298.42万元,同比上升16.74%;扣非净利润5642.18万元,同比上升20.68%;其中2026年第二季度,公司单季度主营收入2.02亿元,同比下降0.62%;单季度归母净利润3019.34万元,同比上升122.09%;单季度扣非净利润2738.96万元,同比上升201.4%;负债率14.77%,投资收益173.46万元,财务费用-283.21万元,毛利率59.26%。财报数据概要请见下图:本文数据来源于华森制药2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660280008","title":"华森制药(002907)披露2026年半年度报告,8月20日股价下跌6.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660280008","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660280008?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:16","pubTimestamp":1787235376,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘,华森制药报收于15.15元,较前一交易日下跌6.19%,最新总市值为63.27亿元。该股当日开盘16.26元,最高16.41元,最低14.8元,成交额达4.75亿元,换手率为9.14%。近日,华森制药披露2026年半年度报告。报告显示,报告期内营业收入为413,550,709.65元,同比下降6.42%;归属于上市公司股东的净利润为62,984,195.42元,同比增长16.74%;扣除非经常性损益后的净利润为56,421,793.99元,同比增长20.68%。经营活动产生的现金流量净额为54,661,543.27元,同比增长98.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000045220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465705","title":"8月18日华森制药(002907)龙虎榜数据:机构净买入609.78万元,北向资金净卖出1492.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465705","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660465705?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:36","pubTimestamp":1787045796,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年8月18日公布的交易公开信息显示,华森制药因日振幅值达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年8月18日收盘,华森制药报收于15.82元,下跌5.78%,换手率15.93%,成交量53.5万手,成交额9.08亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入609.78万元,北向资金合计净卖出1492.49万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433129","title":"华森制药(002907)披露股票交易异常波动公告,8月17日股价上涨10.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433129?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:02","pubTimestamp":1786975376,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘,华森制药报收于16.79元,较前一交易日上涨10.03%,最新总市值为70.11亿元。该股当日开盘16.68元,最高16.79元,最低15.81元,成交额达3.13亿元,换手率为5.62%。近日,华森制药披露《股票交易异常波动公告》称,公司股票于2026年8月13日、8月14日及8月17日连续三个交易日内收盘价格涨幅偏离值累计达20%以上,属于股票交易异常波动。控股股东及实际控制人在异常波动期间未买卖公司股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700034732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659163901","title":"华森制药(002907)披露子公司获得创新药《药物临床试验批准通知书》,8月13日股价上涨1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659163901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659163901?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:39","pubTimestamp":1786631953,"startTime":"0","endTime":"0","summary":"近日,重庆华森制药股份有限公司控股子公司成都华森奥睿药业有限公司收到国家药品监督管理局核准签发的磷酸ORIC-1327滴眼液的《药物临床试验批准通知书》,同意该药品针对青光眼和高眼压症两个适应症共6个规格开展临床试验。该药物为1.1类新药,系华森奥睿自主研发的选择性小分子抑制剂,临床前研究显示其具有显著降眼压作用和良好眼部安全性。这是华森奥睿第二个获批临床的1.1类新药项目,公司子公司累计已获得三个1.1类新药临床批件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239","06978","BK1574","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659134408","title":"华森制药(002907.SZ):磷酸ORIC-1327滴眼液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2659134408","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659134408?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:57","pubTimestamp":1786607862,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)发布公告,公司控股子公司成都华森奥睿药业有限公司(以下简称“华森奥睿”)于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的磷酸ORIC-1327滴眼液对应2个适应症共6个规格的《药物临床试验批准通知书》。磷酸ORIC-1327滴眼液(项目编号ORIP-1009)是由华森奥睿自主研发、拥有完全自主知识产权的选择性小分子抑制剂,临床拟用于青光眼及高眼压症患者的治疗。临床前研究已在新西兰兔和食蟹猴中证实该药物具有显著的降眼压作用,同时具备良好的眼部安全性,展现出良好的成药前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","ORIC","BMED","BK4139","002907","MDTX","IBBJ","PSYK","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565684","title":"股市必读:华森制药新发布《关于公司部分产品拟中选第十二批全国药品集中采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565684?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:43","pubTimestamp":1785868989,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,华森制药报收于13.16元,上涨2.09%,换手率1.51%,成交量5.06万手,成交额6667.64万元。公司公告汇总:公司盐酸戊乙奎醚注射液拟中选第十二批全国药品集中采购,拟中选价格3.57元/支,采购周期至2029年12月31日。该产品为化学药品原6类,已通过仿制药质量和疗效一致性评价,主要用于麻醉前给药及有机磷中毒急救治疗。据药智网数据,其医院端销售额2024年和2025年均为6.02亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327040","title":"华森制药(002907)披露部分产品拟中选第十二批全国药品集中采购,8月3日股价上涨1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327040?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:53","pubTimestamp":1785750784,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,华森制药报收于12.89元,较前一交易日上涨1.02%,最新总市值为53.83亿元。公告显示,2026年7月31日,公司参加了第十二批全国药品集中采购工作。根据联采办发布的拟中选结果,公司产品盐酸戊乙奎醚注射液拟中选本次集采。盐酸戊乙奎醚注射液为公司原料药制剂一体化品种,已通过仿制药质量和疗效一致性评价。本次拟中选有利于提升公司品牌影响力,但相关采购协议尚未签订,后续影响存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300025069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650920802","title":"华森制药(002907)披露公司5个产品新入选《国家基本药物目录》,7月9日股价上涨10.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650920802","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650920802?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:08","pubTimestamp":1783606101,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘,华森制药报收于14.36元,较前一交易日上涨10.04%,最新总市值为59.97亿元。该股当日开盘13.2元,最高14.36元,最低13.2元,成交额达1.74亿元,换手率为3.71%。近日,国家卫生健康委员会发布《国家基本药物目录》,自2026年9月1日起施行。重庆华森制药股份有限公司有5个产品新入选目录,分别为都梁软胶囊、甘桔冰梅片、盐酸特拉唑嗪胶囊、西洛他唑片和注射用阿昔洛韦。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646887625","title":"华森制药(002907)披露痛泻宁颗粒获批国家首家中药二级保护品种,6月25日股价下跌1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646887625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646887625?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:37","pubTimestamp":1782380257,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘,华森制药报收于13.56元,较前一交易日下跌1.38%,最新总市值为56.63亿元。近日,重庆华森制药股份有限公司发布公告称,其生产的痛泻宁颗粒获得国家药监局批准,成为首家中药二级保护品种,保护品种编号为ZYB2072026018,保护期限自公告之日起七年。痛泻宁颗粒为中药创新1.1类新药,功能主治为柔肝缓急、疏肝行气、理脾运湿,用于肝气犯脾所致的腹痛、腹泻、腹胀等症及肠易激综合征(腹泻型)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500032267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645013541","title":"股市必读:华森制药6月18日涨停收盘,收盘价13.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645013541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645013541?lang=zh_cn&edition=full","pubTime":"2026-06-22 01:23","pubTimestamp":1782062589,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,华森制药报收于13.3元,上涨10.01%,涨停,换手率3.52%,成交量11.82万手,成交额1.54亿元。交易信息汇总股价提醒华森制药6月18日涨停收盘,收盘价13.3元;该股于10点22分涨停,1次打开涨停;截至收盘封单资金为2744.24万元,占其流通市值0.61%。资金流向6月18日主力资金净流入5128.45万元,占总成交额0.0%;游资资金净流出1238.22万元,占总成交额0.0%;散户资金净流出3890.23万元,占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644577650","title":"异动快报:华森制药(002907)6月18日10点22分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2644577650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644577650?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:30","pubTimestamp":1781749835,"startTime":"0","endTime":"0","summary":"证券之星6月18日盘中消息,10点22分华森制药(002907)触及涨停板。其所属行业中药目前上涨。领涨股为天目药业。该股为减肥药,创新药,医药概念热股,当日减肥药概念上涨2.81%,创新药概念上涨2.38%,医药概念上涨1.6%。6月17日的资金流向数据方面,主力资金净流出97.08万元,占总成交额1.57%,游资资金净流入727.75万元,占总成交额11.78%,散户资金净流出630.67万元,占总成交额10.21%。近5日资金流向一览见下表:华森制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800013158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643530917","title":"华森制药(002907)披露持股5%以上股东股份变动触及1%整数倍及减持时间届满暨减持结果的公告,6月16日股价上涨3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643530917","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643530917?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:00","pubTimestamp":1781604036,"startTime":"0","endTime":"0","summary":"公告显示,公司持股5%以上股东刘小英女士于2026年4月30日至6月12日通过大宗交易方式减持公司股份4,175,963股,占公司总股本的1%,权益变动后持股比例由7%降至6%。本次减持系履行此前披露的减持计划,减持期间为2026年2月11日起15个交易日后的3个月内,计划减持不超过公司总股本的3%。截至公告日,减持计划时间届满,实际减持10,831,863股,占公司总股本的2.59%,未超出原定计划范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600032516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643783295","title":"股市必读:6月15日华森制药发布公告,股东减持417.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643783295","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643783295?lang=zh_cn&edition=full","pubTime":"2026-06-16 03:46","pubTimestamp":1781552772,"startTime":"0","endTime":"0","summary":"股本股东变化:股东刘小英于2026年4月30日至6月12日减持417.6万股,占总股本1.0%,持股比例由7%降至6%。本次减持系履行此前披露的减持计划,减持期间为2026年2月11日起15个交易日后的3个月内,计划减持不超过公司总股本的3%。截至公告日,减持计划时间届满,实际减持10,831,863股,占公司总股本的2.59%,未超出原定计划范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600004551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642944264","title":"6月10日华森制药现1笔折价10.62%的大宗交易 合计成交200.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642944264","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642944264?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:37","pubTimestamp":1781084257,"startTime":"0","endTime":"0","summary":"证券之星消息,6月10日华森制药发生大宗交易,交易数据如下:大宗交易成交价格10.69元,相对当日收盘价折价10.62%,成交18.8万股,成交金额200.97万元,买方营业部为机构专用,卖方营业部为华泰证券股份有限公司溧水珍珠北路证券营业部。近三个月该股共发生19笔大宗交易,合计成交5.01万手,折价成交19笔。截至2026年6月10日收盘,华森制药报收于11.96元,上涨0.67%,换手率0.71%,成交量2.37万手,成交额2800.97万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000031222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641887684","title":"6月8日华森制药现2笔大宗交易 机构净买入204.98万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641887684","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641887684?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:50","pubTimestamp":1780912255,"startTime":"0","endTime":"0","summary":"证券之星消息,6月8日华森制药发生大宗交易,交易数据如下:近三个月该股共发生18笔大宗交易,合计成交4.83万手,折价成交18笔。该股近期无解禁股上市。截至2026年6月8日收盘,华森制药(002907)报收于12.04元,上涨0.0%,换手率0.94%,成交量3.15万手,成交额3831.35万元。该股近半年内有股东持股变动,合计净减持757.14万股,股东增减持明细如下表:该股最近90天内无机构评级。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787961444328,"stockEarnings":[{"period":"1week","weight":0.0884},{"period":"1month","weight":0.2308},{"period":"3month","weight":0.2558},{"period":"6month","weight":0.0458},{"period":"1year","weight":-0.0966},{"period":"ytd","weight":0.0514}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆华森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29344人(较上一季度减少5.17%)","perCapita":"11554股","listingDate":"2017-10-20","address":"重庆市荣昌区工业园区","registeredCapital":"41759万元","survey":" 重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是中成药、化学药。","listedPrice":4.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华森制药,002907,华森制药股票,华森制药股票老虎,华森制药股票老虎国际,华森制药行情,华森制药股票行情,华森制药股价,华森制药股市,华森制药股票价格,华森制药股票交易,华森制药股票购买,华森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}